Results 81 to 90 of about 29,117 (272)

Prevalence and Risk Factors for Esophageal Strictures in Systemic Sclerosis

open access: yesACR Open Rheumatology, Volume 8, Issue 4, April 2026.
Objective Gastroesophageal reflux disease (GERD) affects up to 90% of patients with systemic sclerosis (SSc). Chronic esophageal acid exposure can result in complications including the formation of esophageal strictures (ES). Proton pump inhibitors can alter gastric acid pH and improve GORD symptoms; however, there have been no recent studies ...
Alannah Quinlivan   +13 more
wiley   +1 more source

Idiopathic Perimenopausal Dystrophic Calcinosis Cuits

open access: yesIndian Journal of Dermatology, 1998
Usual type of dystrophic calcinosis cutis is described in six females in the perimentopausal age group with the lesions in the hip region along with their clinical, biochemical, histological and radiological features.
Parthiban M   +5 more
doaj  

Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)

open access: yesPediatric Rheumatology Online Journal, 2017
Background There is no standardized approach to the management of JDM-associated calcinosis and its phenotypes. Current knowledge of treatment outcomes is confined to small series and case reports.
A. B. Orandi   +5 more
doaj   +1 more source

Calcinosis cutis: A rare feature of adult dermatomyositis [PDF]

open access: yes, 2008
Dermatomyositis is an idiopathic inflammatory myopathy with characteristic cutaneous manifestations. We describe a case of a 55- year-old woman with dermatomyositis who presented with dystrophic calcinosis resistant to medical ...
Lobo, I.   +3 more
core   +1 more source

High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis.

open access: yesRheumatology, 2020
OBJECTIVE To investigate the association between proton pump inhibitor (PPI) use and the presence and severity of calcinosis in SSc. METHODS We analysed data from two SSc cohorts from a single centre.
Lauren V Host   +5 more
semanticscholar   +1 more source

Clinical Associations of Anti‐RNPC3 Autoantibodies in Mixed Connective Tissue Disease

open access: yesACR Open Rheumatology, Volume 8, Issue 4, April 2026.
Objective The RNA‐binding region‐containing protein 3 (RNPC3) protein acts as a molecular bridge, promoting U11/U12 RNP complex formation. In previous reports, patients with systemic sclerosis (SSc) with anti‐RNPC3 autoantibodies had an increased risk of interstitial lung disease (ILD), severe gastrointestinal (GI) disease, and cancer.
Darya S. Jalaledin   +14 more
wiley   +1 more source

Unilateral Idiopathic Calcinosis Cutis: A Case Report

open access: yesCase Reports in Dermatology, 2017
Calcinosis cutis is a rare disorder characterized by the deposition of calcium in the skin and subcutaneous tissue. Unilateral idiopathic calcinosis cutis has only rarely been reported in the literature.
Fahad Alsaif, Amr M. Abduljabbar
doaj   +1 more source

Abatacept in the Treatment of Juvenile Dermatomyositis-Associated Calcifications in a 16-Year-Old Girl

open access: yesCase Reports in Rheumatology, 2020
Calcinosis is a feared complication of JDM that may be seen in up to 40% of children with JDM. It is associated with negative impact on the patients’ quality of life due to weakness, functional disability, joint contractures, muscle atrophy, skin ulcers,
Sukesh Sukumaran, Vini Vijayan
doaj   +1 more source

Giant idiopathic scrotal calcinosis: an exceptional case report in Mauritania

open access: yesAfrican Journal of Urology, 2022
Background Scrotal calcinosis is a rare idiopathic and benign condition, first described over a century ago by Lewinski. We report an exceptional case due to its size of a scrotal calcinosis.
Aboubakry SOW   +3 more
doaj   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

open access: yesMedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Home - About - Disclaimer - Privacy